US2021046059A1
|
|
Methods of treating gastrointestinal stromal tumors
|
WO2021030404A1
|
|
Methods and compositions for treating vascular malformations
|
WO2021030405A1
|
|
Ripretinib for treating gastrointestinal stromal tumors
|
WO2020257180A1
|
|
Aminopyrimidine amide autophagy inhibitors and methods of use thereof
|
US2020354346A1
|
|
Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
US2020354352A1
|
|
Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
US2020253973A1
|
|
Methods of treating disorders using csf1r inhibitors
|
JP2019131610A
|
|
Methods for inhibiting tie2 kinase useful in treatment of cancer
|
BR112020015572A2
|
|
combination therapy for the treatment of mastocytosis
|
AU2019215081A1
|
|
Combination therapy for the treatment of gastrointestinal stromal tumors
|
US2017079966A1
|
|
Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
|
WO2016061231A1
|
|
Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
|
EP3206752A1
|
|
Inhibition of trk kinase mediated tumor growth and disease progression
|
US2015246033A1
|
|
Methods for inhibiting tie-2 kinase useful in the treatment of cancer
|
US2014275016A1
|
|
N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
|
US2014343103A1
|
|
Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities
|
CN105120864A
|
|
2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
|
CN105228620A
|
|
Represent N-acyl group-N '-(pyridine-2-base) urea and the analog of anticancer and antiproliferative activity
|
WO2014145015A2
|
|
Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
|
WO2014145023A1
|
|
1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
|